Difference between revisions of "Part:BBa K2976006:Design"
(→‎References)
 
(One intermediate revision by the same user not shown)
Line 12: Line 12:
 
===Source===
 
===Source===
  
−
Synthetic construct  
+
Synthetic construct, Chinese patent
  
 
===References===
 
===References===
−
[1] Jie X.A PD-L1 targeting peptide and its application:CN201810650428.9[P].2018-11-20.
+
<p>[1] Jie X.A PD-L1 targeting peptide and its application:CN201810650428.9[P].2018-11-20.</p>
−
[2] Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290(13):8166-72
+
<p>[2] Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290(13):8166-72</p>

Latest revision as of 02:07, 5 September 2019


Anti-PD-L1 peptide


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

GNSTM should be fused to the N terminus of anti-PD-L1 peptide to enhance the stability. The amino acid sequence Asn-Ser-Thr (NST) is a standard N-linked glycosylation sequon, and the amino acids Ger and Met flanking sequon could increase glycosylation frequency in mammals.

Source

Synthetic construct, Chinese patent

References

[1] Jie X.A PD-L1 targeting peptide and its application:CN201810650428.9[P].2018-11-20.

[2] Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290(13):8166-72